ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Human Growth Hormone

Also written as “somatropin”, “Somatropin” and “PEG-somatropin”.

Its studies are mostly in Dwarfism, Pituitary · Turner Syndrome · Dwarfism · Growth Disorders · Genetic Diseases, Inborn, led by 15 companies.

Drug pageHuman Growth Hormone: every studyMany companies study it; this page follows only the 117 they lead. All 217 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 13, 2005117 company-led studies, 5 open or runningNext primary completion: Apr 28, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk340 open or runningphase 4since Sep 13, 2005Feb 1, 2005none ahead
Changchun GeneScience Pharmaceuticalits history only194 open or runningphase 4since Nov 27, 2014Apr 21, 2011Apr 28, 2027phase 4 · NCT07691125
Merck KGaA, Darmstadt, Germanyits history only190 open or runningphase 4since Nov 18, 2005May 13, 2004none ahead
Pfizerits history only180 open or runningphase 4since Feb 5, 2007Sep 9, 2005none ahead
Eli Lillyits history only100 open or runningphase 4since Dec 15, 2005Sep 12, 2005none ahead
LG Chemits history only40 open or runningphase 4since Nov 10, 2016Dec 29, 2005none ahead
Daewoong Pharmaceuticalits history only20 open or runningphase 3since Jan 19, 2016Sep 23, 2011none ahead
Ferring Pharmaceuticalsits history only20 open or runningphase 3since Nov 7, 2005Nov 7, 2005none ahead
Hoffmann-La Rocheits history only20 open or runningphase 4since Dec 4, 2014Mar 11, 2004none ahead
Ipsenits history only20 open or runningphase 4since Aug 24, 2011Oct 5, 2005none ahead

Also a collaborator on its studies: Merck Serono S.A.S, France, Merck Serono Co., Ltd., China, Merck Serono S.P.A., Italy, Merck Serono S.A., Geneva, Merck, S.L., Spain and BioPartners.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novo Nordisk only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 17 studies since Feb 1, 2005.

  1. Dec 16, 2009Phase 1 study in Growth Hormone DisorderNCT01034202 · 56 enrolled · Denmark
  2. Jul 20, 2011Phase 1 study in Genetic Diseases, InbornNCT01401244 · 30 enrolled · United States
  3. Dec 29, 2011Phase 1 study in Renal Insufficiency, ChronicNCT01502137 · 21 enrolled · Germany
  4. Dec 29, 2011Phase 3 study in Growth Hormone DisorderNCT01502124 · 78 enrolled · United States
  5. Jan 2, 20123 phase 3 studies in Genetic Diseases, InbornNCT01529944, NCT01529840, NCT01518036
  6. Jan 9, 2012Phase 1 study in Growth DisordersNCT01512095
  7. Jan 20, 2012Phase 4 study in Genetic Diseases, InbornNCT01518062 · 65 enrolled · Netherlands
  8. Mar 22, 2012Phase 4 study in Dwarfism, PituitaryNCT01562834 · 22 enrolled · France
  9. Mar 23, 2012Phase 3 study in Genetic Diseases, InbornNCT01563926 · 168 enrolled · Israel
  10. Sep 28, 2012Phase 4 study in Foetal Growth ProblemNCT01697644 · 75 enrolled · Netherlands
  11. Oct 1, 2012Phase 4 study in Dwarfism, PituitaryNCT01698944 · 7 enrolled · Greece
  12. Nov 22, 20122 phase 4 studiesNCT01734486, NCT01734447
  13. Jan 24, 2013Phase 3 study in Growth DisordersNCT01778023 · 54 enrolled · Korea, Republic of
  14. Aug 20, 2013Phase 3 study in Genetic Diseases, InbornNCT01927861 · 51 enrolled · Japan
  15. Jul 28, 2021Named human growth hormoneINNProposed as its International Nonproprietary Name in WHO's List 125

TargetBeta

GHR →read by rule
“Growth hormone receptor agonist”ChEMBL 37, by rule

Other programs on GHR

ProgramCompanyFurthest phaseStudies
lonapegsomatropinruleascendis-pharma-endocrinology-division-a-sphase 36

Studies

All 34 Novo Nordisk leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01927861Genetic Diseases, Inborn · Japan3CompletedJul 12, 201851
NCT01778023Growth Disorders · Korea, Republic of3CompletedDec 17, 201454
NCT01734486Genetic Diseases, Inborn · France4CompletedMay 21, 200331
NCT01734447Foetal Growth Problem · France4CompletedApr 30, 200357
NCT01698944Dwarfism, Pituitary · Greece4TerminatedNov 18, 20027
NCT01697644Foetal Growth Problem · Netherlands4CompletedMay 200575
NCT01563926Genetic Diseases, Inborn · Israel3CompletedOct 10, 2002168
NCT01562834Dwarfism, Pituitary · France4CompletedDec 1, 200222
NCT01518062Genetic Diseases, Inborn · Netherlands4CompletedSep 200365
NCT01518036Genetic Diseases, Inborn · United Kingdom3CompletedApr 11, 200457
NCT01512095Growth Disorders1WithdrawnNov 20130
NCT01529944Genetic Diseases, Inborn · Sweden3CompletedOct 200822
NCT01529840Genetic Diseases, Inborn · Sweden3CompletedSep 200524
NCT01502137Renal Insufficiency, Chronic · Germany1CompletedNov 200521
NCT01502124Growth Hormone Disorder · United States3CompletedMar 5, 200378
NCT01401244Genetic Diseases, Inborn · United States1CompletedSep 27, 201130
NCT01034202Growth Hormone Disorder · Denmark1CompletedJan 200856
NCT00931476Dwarfism, Pituitary · United States1CompletedJun 8, 200086
NCT00567385Growth Hormone Disorder · Turkey4CompletedMar 22, 2004176
NCT00557336Foetal Growth Problem · Spain3CompletedJun 29, 2005160
NCT00519844Foetal Growth Problem · France4CompletedJan 20065
NCT00519558Dwarfism, Pituitary · Japan3CompletedJan 24, 2005121
NCT00503698Renal Insufficiency, Chronic · United States, Argentina, Brazil and more3TerminatedDec 2008712
NCT00262249Growth Disorders · United States3CompletedMay 2004173
NCT00254514Fractures, Bone · Finland, France, Germany and more2CompletedOct 2003407
NCT00184769Renal Insufficiency, Chronic · Portugal, Spain4CompletedDec 21, 200516
NCT00184756Foetal Growth Problem · Czech Republic, Finland, Germany and more3CompletedJul 2006151
NCT00184743Dwarfism, Pituitary · Japan3CompletedDec 28, 2005112
NCT00184730Dwarfism, Pituitary · Japan3CompletedSep 200686
NCT00184717Foetal Growth Problem · Japan3CompletedMar 29, 200698
NCT00184691Foetal Growth Problem · Spain3CompletedJun 200578
NCT00184678Dwarfism, Pituitary · Australia, Austria, Belgium and more3CompletedJul 2006161
NCT00184652Renal Insufficiency, Chronic · Denmark, Germany, Hong Kong and more2CompletedSep 2005140
NCT00102817Dwarfism, Pituitary · United States3CompletedDec 2006149

How it is read

Names in the registry

  • “somatropin”, 52 entries
  • “Somatropin”, 27 entries
  • “PEG-somatropin”, 13 entries
  • “Saizen®”, 6 entries
  • “Genotropin”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.